Business Context and Reporting Period
This Form 8-K, dated March 19, 2021, is filed by Big Rock Partners Acquisition Corp. (BRPA), a Delaware corporation and Special Purpose Acquisition Company (SPAC). The filing reports on a material definitive agreement regarding the proposed business combination with NeuroRx, Inc. (NeuroRx), a biopharmaceutical company developing treatments for neurological disorders. The transaction involves a merger where NeuroRx will become a wholly-owned subsidiary of BRPA.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, or liquidity metrics for either BRPA or NeuroRx. The document references the existence of a registration statement on Form S-4 which contains detailed financial information, but no specific financial data is provided within this text.
Material Changes
- Extension of Merger Deadline: On March 19, 2021, the parties entered into a Second Amendment to the Agreement and Plan of Merger.
- Outside Date Adjustment: The amendment extends the "outside date" by which the merger must be consummated from April 23, 2021, to May 24, 2021.
- Transaction Structure: The core structure remains unchanged; Big Rock Merger Corp. (a subsidiary of BRPA) will merge with NeuroRx, with NeuroRx surviving as a subsidiary of BRPA.
Guidance, Outlook, and Risks
The filing includes a cautionary note regarding forward-looking statements, warning that actual results may differ materially from expectations. Key risks and contingencies identified include:
- Transaction Completion: Risks regarding the approval, timing, and ability to complete the business combination.
- Regulatory Approval: Inherent uncertainty associated with the FDA approval process for NeuroRx's drug candidates.
- Market Listing: Risks related to BRPA's ability to remain listed on the Nasdaq Capital Market prior to and after the closing of the transaction.
- Operational Disruption: Potential disruption to NeuroRx's current plans and operations due to the transaction.
- External Factors: Impact of the COVID-19 pandemic, changes in laws/regulations, and general economic conditions.
Management directs investors to the Form S-4 registration statement for comprehensive details on the proposed transaction and financial projections.
Investor Verification Checklist
- Verify the final terms of the Second Amendment to the Merger Agreement attached as Exhibit 2.1.
- Review the Form S-4 registration statement filed with the SEC for detailed financial data and risk factors.
- Confirm the status of the proxy statement/prospectus/consent solicitation statement to be mailed to stockholders.
- Monitor the May 24, 2021 deadline for the consummation of the merger.
- Assess the progress of NeuroRx's drug development pipeline and FDA regulatory status.